Roivant Sciences Ltd (OQ:ROIV)

Apr 02, 2024 07:00 am ET
Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma
Roivant (Nasdaq: ROIV) and Priovant Therapeutics today announced positive results from the Phase 2 study (NEPTUNE) evaluating brepocitinib in non-anterior non-infectious uveitis (NIU), showing the strongest efficacy data in NIU observed to date....
Mar 26, 2024 06:22 pm ET
Roivant Sciences Set to Join S&P MidCap 400; Sunrun to Join S&P SmallCap 600
NEW YORK, March 26, 2024 /PRNewswire/ -- Roivant Sciences Ltd (NASD:ROIV) will replace Sunrun Inc. (NASD:RUN) in the S&P MidCap 400, and Sunrun will replace PGT Innovations Inc. (NYSE:PGTI) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, April 1. MITER Brands is acquiring PGT Innovations in a transaction expected to be completed on or about March 28 pending final conditions.
Feb 13, 2024 07:00 am ET
Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update
Roivant (Nasdaq: ROIV) today reported its financial results for the third quarter ended December 31, 2023, and provided a business update. Roivant completed the sale of Telavant to Roche for $7.1B with an additional $150M in cash payable upon the...
Jan 30, 2024 04:05 pm ET
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024
Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, February 13, 2024, to report its financial results for the third quarter ended December 31, 2023, and provide a business update....
Dec 20, 2023 04:30 pm ET
Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease
Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that results from the initial cohort of patients in an ongoing 24-week Phase 2 clinical...
Dec 14, 2023 09:00 am ET
Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease
Roivant (Nasdaq: ROIV) announced today the completion of the previously announced acquisition by Roche (SIX: RO, ROG; OTCQX: RHHBY) of Telavant, for an upfront payment of approximately $7.1 billion. Telavant holds the rights in the US and Japan to...
Nov 28, 2023 07:00 am ET
Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential
Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced initial data from 600 mg MAD cohort of a Phase 1 clinical trial of IMVT-1402 in healthy...
Nov 27, 2023 08:00 am ET
Roivant and Priovant Announce Results from Phase 2 Study of Oral Brepocitinib in Systemic Lupus Erythematosus
Roivant (Nasdaq: ROIV) and Priovant today announced the Phase 2 study evaluating oral brepocitinib in adult patients with moderate to severe active lupus did not meet its primary endpoint of Systemic Lupus Erythematosus Responder Index change of 4...
Nov 13, 2023 07:00 am ET
Roivant Reports Financial Results for the Second Quarter Ended September 30, 2023, and Provides Business Update
Roivant (Nasdaq: ROIV) today reported its financial results for the second quarter ended September 30, 2023, and provided an update on the business. “In the last few weeks, we announced a historic deal with Roche for the sale of Telavant for...
Nov 10, 2023 08:00 am ET
Roivant Announces Appointment of Mayukh Sukhatme to Its Board of Directors
Roivant (Nasdaq: ROIV) today announced the appointment of Mayukh Sukhatme, M.D., to its Board of Directors, effective immediately. Dr. Sukhatme will fill a newly created Class III seat on the Board of Directors, increasing the Board of Directors to...
Oct 30, 2023 05:30 pm ET
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2023, and Provide Business Update on Monday, November 13, 2023
Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Monday, November 13, 2023, to report its financial results for the second quarter ended September 30, 2023, and provide a business...
Oct 23, 2023 01:00 am ET
Roche Enters Into a Definitive Agreement to Acquire Telavant Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease From Roivant
Roivant (Nasdaq: ROIV) announced today the entry into a definitive agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) to acquire Telavant Holdings, Inc. (Telavant), a Roivant company, owned by Roivant Sciences Ltd. and Pfizer Inc. The agreement...
Oct 13, 2023 08:00 am ET
Covant Therapeutics Appoints Vincent Hennemand as Chief Executive Officer
Covant Therapeutics, an innovative covalent drug discovery company, is pleased to announce the appointment of Vincent Hennemand as Chief Executive Officer (CEO). Vincent Hennemand is a seasoned executive with a distinguished career in the...
Sep 26, 2023 06:00 am ET
Roivant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results
Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that subcutaneously administered doses of IMVT-1402 produced dose-dependent reductions in...
Sep 11, 2023 08:00 am ET
Roivant Announces Completion of Redemption of its Outstanding Warrants
Roivant (Nasdaq: ROIV) today announced that it completed the redemption of its outstanding public warrants (the “Public Warrants”) and private placement warrants (the “Private Placement Warrants” and, together with the Public Warrants, the...
Aug 17, 2023 04:05 pm ET
Roivant Announces Redemption Fair Market Value in Connection with Redemption of its Outstanding Warrants
Roivant (Nasdaq: ROIV) today announced the “Redemption Fair Market Value” to be used in connection with the previously announced redemption of its outstanding public warrants (the “Public Warrants”) and private placement warrants (the “Private...
Aug 14, 2023 07:00 am ET
Roivant Reports Financial Results for the First Quarter Ended June 30, 2023, and Provides Business Update
Roivant (Nasdaq: ROIV) today reported its financial results for the first quarter ended June 30, 2023, and provided an update on the business. “This was an incredibly busy quarter with multiple clinical readouts and trial initiations. We reported...
Aug 03, 2023 04:05 pm ET
Roivant to Report Financial Results for the Quarter Ended June 30, 2023, and Provide Business Update on Monday, August 14, 2023
Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Monday, August 14, 2023, to report its financial results for the quarter ended June 30, 2023, and provide a business update. To access...
Aug 02, 2023 04:05 pm ET
Roivant Announces Redemption of Outstanding Warrants
Roivant (Nasdaq: ROIV) today announced that it will redeem all of its outstanding public warrants (the “Public Warrants”) and private placement warrants (the “Private Placement Warrants” and, together with the Public Warrants, the “Warrants”) to...
Jul 27, 2023 08:00 am ET
Telavant, a Roivant Company, Advances Inflammatory Bowel Disease Program with First Patient Dosed in Global Phase 2 Trial of Novel Anti-TL1A Antibody RVT-3101 in Crohn’s Disease
Telavant, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics to help patients living with inflammatory and fibrotic diseases, announced today the initiation of the TAHOE study, a Phase 2...
Jul 11, 2023 08:00 am ET
Roivant Ranks No. 25 on Fast Company’s Fifth Annual List of the 100 Best Workplaces for Innovators and is the Winner on the Science and Technology List as a Part of the Best Workplaces for Innovators
Fast Company today announced its fifth annual Best Workplaces for Innovators list, honoring organizations and businesses that demonstrate an inspiring commitment to encourage and develop innovation at all levels. Roivant (Nasdaq: ROIV) came in at...
Jun 28, 2023 08:57 am ET
UPDATE -- Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provides Business Update
Roivant (Nasdaq: ROIV) today reported its financial results for the fourth quarter and fiscal year ended March 31, 2023, and provided an update on the business. Roivant’s Chief Executive Officer, Matt Gline, noted: “I’m incredibly pleased with the...
Jun 28, 2023 07:00 am ET
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provides Business Update
Roivant (Nasdaq: ROIV) today reported its financial results for the fourth quarter and fiscal year ended March 31, 2023, and provided an update on the business. Roivant’s Chief Executive Officer, Matt Gline, noted: “I’m incredibly pleased with the...
Jun 26, 2023 04:05 pm ET
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provide Business Update on Wednesday, June 28, 2023
Roivant Sciences (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, June 28, 2023, to report its financial results for the fourth quarter and fiscal year ended March 31, 2023, and...
Jun 22, 2023 07:30 am ET
Roivant Reports Chronic Period Data for RVT-3101 from the TUSCANY-2 Phase 2b Study in Ulcerative Colitis, Demonstrating Improved Efficacy from the Induction to Chronic Period
Roivant Sciences (Nasdaq: ROIV) today announced positive results from the chronic period of the TUSCANY-2 Phase 2b study of RVT-3101, a once-monthly subcutaneously administered anti-TL1A antibody. TUSCANY-2 is a large, global, randomized,...
Jun 21, 2023 05:00 pm ET
Roivant to Host Investor Call at 8:00 AM ET on Thursday, June 22 to Review Results from the Chronic Period of TUSCANY-2, a Large Global Phase 2b Study of RVT-3101 (Anti-TL1A Antibody) in Ulcerative Co
Roivant Sciences (Nasdaq: ROIV) today announced that it will host a live investor call and webcast at 8:00 AM ET on Thursday, June 22 to review results from the chronic period of TUSCANY-2, a large global Phase 2b study of RVT-3101 (anti-TL1A...
May 16, 2023 07:00 am ET
Roivant Reports Positive Topline Results from ADORING 1, the Second Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% in Adults and Children as Young as 2 Years Old
Dermavant Sciences, a Roivant Sciences (Nasdaq: ROIV) company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced positive results from ADORING 1, the second of two double-blind, randomized,...
Apr 04, 2023 07:37 am ET
Lokavant Emerges from Roivant Sciences with Multiple Industry Partnerships to Accelerate Impact on Clinical Research
Lokavant, the clinical trial intelligence platform company, has achieved significant business milestones within three months of the company’s $21 million Series A funding announcement, including new customer growth and leadership hires. The venture has also formally launched from parent company Roivant Sciences (Nasdaq: ROIV)
Apr 04, 2023 07:37 am ET
Lokavant Hires Experienced Leaders to Accelerate Growth Trajectory
Lokavant, the clinical trial intelligence platform company, announces strategic new hires to drive its mission to make clinical trials smarter. Lokavant, launched in 2020, has hired Andrew (AJ) Mills as executive vice president of sales;
Mar 28, 2023 08:00 am ET
Covant and Boehringer Ingelheim Collaborate to Develop a Novel ADAR1 Inhibitor for Use in Cancer Patients
Covant Therapeutics, an innovative covalent drug discovery company, has entered into an exclusive research collaboration and worldwide licensing agreement with Boehringer Ingelheim covering Covant’s ADAR1 program. The companies jointly aim to...
Mar 28, 2023 08:00 am ET
Covant and Boehringer Ingelheim Collaborate to Develop a Novel ADAR1 Inhibitor for Use in Cancer Patients
Covant Therapeutics, an innovative covalent drug discovery company, has entered into an exclusive research collaboration and worldwide licensing agreement with Boehringer Ingelheim covering Covant’s ADAR1 program. The companies jointly aim to...
Mar 15, 2023 07:45 am ET
Roivant Reports Positive Topline Results from ADORING 2 Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% Once Daily in Adults and Children as Young as 2 Years Old
46.4% of subjects receiving VTAMA cream, 1% achieved the primary endpoint of Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-ADTM) response of clear (0) or almost clear (1) with at least a 2-grade improvement from baseline at...
Mar 14, 2023 04:07 pm ET
Roivant to Host Investor Call at 8:00 AM ET on Wednesday, March 15 to Review Results from ADORING 2 Phase 3 Trial in Atopic Dermatitis
Roivant Sciences (Nasdaq: ROIV) today announced that it will host a live investor call and webcast at 8:00 AM ET on Wednesday, March 15 to review topline results from the ADORING 2 study, one of two replicate Phase 3 studies in atopic dermatitis....
Mar 14, 2023 08:00 am ET
Proteovant Therapeutics to Present Preclinical Data from Estrogen Receptor and IKZF2 Protein Degrader Programs
Proteovant Therapeutics, a Roivant Sciences (Nasdaq: ROIV) company leveraging the process of protein degradation to discover and develop transformative medicines for the treatment of patients with life-altering diseases, today announced it will...
Mar 07, 2023 08:00 am ET
Covant Therapeutics Announces the Formation of its Scientific Advisory Board to Support Platform and Pipeline Advancement
Covant Therapeutics, an innovative covalent drug discovery company incubated by Roivant Sciences (Nasdaq: ROIV), today announced the formation of its Scientific Advisory Board (SAB). Covant uses its unprecedented high-throughput chemoproteomics...
Feb 21, 2023 08:32 pm ET
Roivant Sciences Announces Change to its Board of Directors
Roivant Sciences (Nasdaq: ROIV) today announced that its founder Vivek Ramaswamy has stepped down from the company’s board of directors to focus on his U.S. presidential campaign. Vivek founded Roivant in 2014 with the vision of revolutionizing...
Feb 13, 2023 07:00 am ET
Roivant Sciences Reports Financial Results for the Third Quarter Ended December 31, 2022 and Provides Business Update
Roivant Sciences (Nasdaq: ROIV) today reported its financial results for the third quarter ended December 31, 2022, and provided an update on the Company’s operations. Roivant’s Chief Executive Officer, Matt Gline, noted: “This past quarter was a...
Feb 02, 2023 09:14 pm ET
Roivant Sciences Announces Pricing of Upsized Public Offering of Common Shares
Roivant Sciences (Nasdaq: ROIV) today announced the pricing of an upsized underwritten public offering of 26,666,666 of its common shares at a price to the public of $7.50 per share. All of the common shares to be sold in the offering are to be...
Feb 01, 2023 04:05 pm ET
Roivant Sciences Announces Proposed Public Offering of Common Shares
Roivant Sciences Ltd. (Nasdaq: ROIV) announced today that it has commenced an underwritten public offering of $150 million of common shares. In addition, Roivant expects to grant the underwriters a 30-day option to purchase up to an additional...
Jan 30, 2023 08:00 am ET
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2022 on Monday, February 13, 2023
Roivant Sciences (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Monday, February 13, 2023, to report its financial results for the third quarter ended December 31, 2022 and provide a corporate...
Jan 04, 2023 06:05 am ET
Roivant Announces Statistically Significant and Clinically Meaningful Results from the Induction Period of TUSCANY-2, a Large Global Phase 2b Study of Subcutaneous RVT-3101 for the Treatment of Ulcera
Roivant Sciences (Nasdaq: ROIV) today announced positive results from the induction period of the TUSCANY-2 Phase 2b study of RVT-3101 (previously PF-06480605), a once monthly subcutaneously administered anti-TL1A antibody which demonstrated...
Dec 07, 2022 07:33 am ET
Thinking about buying stock in Prometheus Biosciences, Meta Materials, Eterna Therapeutics, Roivant Sciences, or China Automotive Systems?
NEW YORK, Dec. 7, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for RXDX, MMAT, ERNA, ROIV, and CAAS.
Dec 07, 2022 05:30 am ET
Edison Partners leads $21 million funding round for clinical trial intelligence disruptor Lokavant
Investment will transform the clinical research industry for smarter and faster trials
Dec 01, 2022 08:00 am ET
Roivant and Pfizer Form New Vant Company Focused on Developing TL1A Drug Candidate for Inflammatory and Fibrotic Diseases
Roivant Sciences (Nasdaq: ROIV) and Pfizer Inc. (NYSE: PFE) today announced formation of a new Vant to develop and commercialize PF-06480605 (now RVT-3101). RVT-3101 is a fully human monoclonal antibody targeting TL1A, which is currently in Phase...
Nov 14, 2022 07:00 am ET
Roivant Sciences Reports Financial Results for the Second Quarter Ended September 30, 2022 and Provides Business Update
Roivant Sciences Ltd. (Nasdaq: ROIV) today reported its financial results for the second quarter ended September 30, 2022 and provided an update on the Company’s operations. Roivant’s chief executive officer, Matt Gline, noted: “This has been a...
Nov 10, 2022 09:00 am ET
Affivant to Present Data on AFVT-2101 at 37th Annual Meeting of SITC
Affivant, a biotechnology company dedicated to developing novel immune-oncology approaches to activate and enable the innate immune system to fight cancer, will present a poster at the 37th Annual Meeting of The Society for Immunotherapy of Cancer...
Nov 08, 2022 06:15 am ET
Roivant Sciences Announces Pricing of Primary and Secondary Public Equity Offering
Roivant Sciences Ltd. (Nasdaq: ROIV), a next-generation biopharmaceutical company dedicated to improving the delivery of healthcare to patients, announced today the pricing of its primary and secondary public offering of 30,000,000 common shares of...
Nov 07, 2022 04:01 pm ET
Roivant Sciences Announces Proposed Public Equity Offering
Roivant Sciences Ltd. (Nasdaq: ROIV), a next-generation biopharmaceutical company dedicated to improving the delivery of healthcare to patients, announced today the commencement of a proposed underwritten public offering of $150,000,000 of common...
Oct 18, 2022 04:00 pm ET
Roivant Sciences to Report Financial Results for the Second Quarter Ended September 30, 2022 on Monday, November 14, 2022 and Present at Upcoming Conferences
Roivant Sciences (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. EST on Monday, November 14, 2022 to report its financial results for the second quarter ended September 30, 2022 and provide a...
Aug 30, 2022 07:00 am ET
Roivant to Participate in September Investor Events
Roivant Sciences (Nasdaq: ROIV) will participate in three healthcare investor conferences and hold an investor day in September: Citi BioPharma Conference in Boston on Wednesday, September 7thH.C. Wainwright Global Investment Conference in New...
Aug 15, 2022 07:00 am ET
Roivant Sciences Reports Financial Results for the First Quarter Ended June 30, 2022 and Provides Business Update
Roivant Sciences Ltd. (Nasdaq: ROIV), a next-generation biopharmaceutical company dedicated to improving the delivery of healthcare to patients, today reported its financial results for the first quarter ended June 30, 2022 and provided an update...
Aug 03, 2022 07:00 am ET
Roivant Sciences to Report Financial Results for the Quarter Ended June 30, 2022 on Monday, August 15, 2022
Roivant Sciences (Nasdaq: ROIV), a biopharmaceutical company dedicated to improving the delivery of healthcare to patients, today announced that it will host a live conference call and webcast at 8:00 a.m. EDT on Monday, August 15, 2022 to report...
Jun 28, 2022 06:10 am ET
Roivant Sciences Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2022 and Provides Business Update
Roivant Sciences Ltd. (Nasdaq: ROIV), a next-generation biopharmaceutical company dedicated to improving the delivery of healthcare to patients, today reported its financial results for the fourth quarter and fiscal year ended March 31, 2022 and...
Jun 28, 2022 06:00 am ET
Roivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus
Roivant Sciences and Pfizer today announced the unveiling of Priovant Therapeutics, dedicated to developing and commercializing novel therapies for autoimmune diseases with the greatest morbidity and mortality. Priovant was established in September 2021 through a transaction between Roivant (Nasdaq: ROIV) and Pfizer (NYSE: PFE), in which Pfizer licensed oral and topical brepocitinib’s global development rights and US and Japan commercial rights to Priovant. Pfizer holds a 25% equity ownership interest in Priovant.
Jun 28, 2022 06:00 am ET
Roivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus
Roivant Sciences and Pfizer today announced the unveiling of Priovant Therapeutics, dedicated to developing and commercializing novel therapies for autoimmune diseases with the greatest morbidity and mortality. Priovant was established in September...
Jun 15, 2022 04:30 pm ET
Roivant Sciences to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2022 on Tuesday, June 28, 2022
Roivant Sciences (Nasdaq: ROIV), a biopharmaceutical company dedicated to improving the delivery of healthcare to patients, today announced that it will host a live conference call and webcast at 8:00 a.m. EDT on Tuesday, June 28, 2022 to report...
May 24, 2022 09:31 am ET
Thinking about buying stock in Zovio, Roivant Sciences, Petco, Torm, or SoFi Technologies?
NEW YORK, May 24, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ZVO, ROIV, WOOF, TRMD, and SOFI.
May 24, 2022 06:00 am ET
FDA Approves Dermavant’s VTAMA® (tapinarof) cream, 1% for the Treatment of Plaque Psoriasis in Adults: First Topical Novel Chemical Entity Launched for Psoriasis in the U.S. in 25 Years
REMITTIVE EFFECT: The median duration of clear or almost clear skin was approximately four months after cessation of treatment with VTAMA cream as measured by the time to first worsening while off-therapy during the Phase 3 Long Term Extension...
May 19, 2022 04:30 pm ET
Roivant to Present at Upcoming Investor Conferences
Roivant Sciences (Nasdaq: ROIV) will participate in four upcoming healthcare investor conferences: UBS Global Healthcare Conference in New York City on Monday, May 23 at 9:15 a.m. EDT. CEO Matt Gline will present.H.C. Wainwright Global Investment...
May 16, 2022 07:00 am ET
Aruvant Announces Oral Presentation at American Society of Gene and Cell Therapy (ASGCT)
Aruvant Sciences ("Aruvant"), a private company focused on developing gene therapies for rare diseases, announced that data demonstrating the clinical benefit of the company's lead product candidate ARU-1801 for severe sickle cell disease (SCD)...
May 02, 2022 07:00 am ET
Roivant Appoints Chief Development Officer and Announces Multiple Collaborations in Targeted Protein Degradation
Roivant Sciences (Nasdaq: ROIV) today announced that Srini Ramanathan, Ph.D. will be joining the company as Chief Development Officer. Dr. Ramanathan has over 20 years of drug development expertise across a wide range of diseases. He joins Roivant...
Apr 20, 2022 07:00 am ET
VantAI Forms Research Collaboration with Boehringer Ingelheim to Identify Novel Protein Degraders
VantAI, an AI-first induced-proximity company, and Boehringer Ingelheim today announced that the two companies have entered into an early discovery research collaboration focused on degrading traditionally “undruggable” targets.The collaboration...
Apr 13, 2022 07:00 am ET
VantAI Announces Multi-Year Protein Degrader Discovery Collaboration with Janssen
VantAI, an AI-first induced-proximity company, today announced it has entered into a multi-year collaboration agreement with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (‘Janssen’). The agreement was...
Mar 25, 2022 08:01 am ET
Dermavant Showcases New Long-Term Durability and Tolerability Data from Phase 3 PSOARING 3 Trial of Tapinarof Cream for Adults with Plaque Psoriasis at the 2022 AAD Annual Meeting
Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced Phase 3 PSOARING 3 long-term extension study results demonstrating durable...
Mar 24, 2022 07:00 am ET
Sanford Burnham Prebys and Roivant Social Ventures Announce Groundbreaking Partnership to Increase Diversity & Inclusion in Biopharma
Roivant Social Ventures, a nonprofit philanthropic social impact organization launched by Roivant Sciences, today announced a major collaboration with Sanford Burnham Prebys, San Diego’s prestigious medical discovery institute. The groundbreaking...
Mar 11, 2022 04:45 pm ET
Roivant to Present at Targeted Protein Degradation Conference
Roivant Sciences (Nasdaq: ROIV) today announced that its CEO Matt Gline will present at Guggenheim’s Targeted Protein Degradation Day on Wednesday, March 16, 2022 at 1:15 p.m. ET. A live webcast will be available under “Events & Presentations” on...
Feb 28, 2022 06:01 am ET
Genevant Sciences and Arbutus Biopharma File Patent Infringement Lawsuit Against Moderna
Genevant Sciences, a leading nucleic acid delivery company, and Arbutus Biopharma Corporation (Nasdaq: ABUS) today filed a lawsuit in the U.S. District Court for the District of Delaware against Moderna, Inc. (Nasdaq: MRNA) and an affiliate seeking...
Feb 14, 2022 07:00 am ET
Roivant Sciences Reports Financial Results for the Quarter Ended December 31, 2021 and Provides Business Update
Roivant Sciences Ltd. (Nasdaq: ROIV), a next-generation biopharmaceutical company dedicated to improving the delivery of healthcare to patients, today reported its financial results for the third fiscal quarter ended December 31, 2021 and provided...
Feb 07, 2022 07:00 am ET
Roivant to Report Financial Results for the Quarter Ended December 31, 2021 on Monday, February 14, 2022
Roivant Sciences (Nasdaq: ROIV), a biopharmaceutical company dedicated to improving the delivery of healthcare to patients, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Monday, February 14, 2022 to report...
Jan 25, 2022 04:30 pm ET
Roivant to Present at Upcoming Investor Conferences
Roivant Sciences (Nasdaq: ROIV) today announced that its CEO Matt Gline will present at two upcoming conferences: B. Riley Securities Virtual Oncology Conference on Thursday, January 27, 2022 at 12:30 p.m. ETSVB Leerink Global Healthcare...
Jan 05, 2022 04:30 pm ET
Roivant Licenses Splicing Modulator and Announces Upcoming Presentation at 40th Annual J.P. Morgan Healthcare Conference
Roivant Sciences (Nasdaq: ROIV), a next-generation biopharmaceutical company dedicated to improving the delivery of healthcare to patients, today announced that it has entered into a licensing agreement with Eisai Co., Ltd. for exclusive global...
Dec 16, 2021 10:00 am ET
Virtual Reality Startup Nanome Announces Largest Deployment to Date
Nanome, the first virtual reality software company to launch an immersive real-time collaboration platform for scientific discovery, today announced that the company has executed its largest deployment to date with Roivant Discovery, the drug...
Nov 15, 2021 07:00 am ET
Roivant Sciences Reports Financial Results for the Quarter Ended September 30, 2021 and Provides Business Update
Roivant Sciences Ltd. (Nasdaq: ROIV), a next-generation biopharmaceutical company dedicated to improving the delivery of healthcare to patients, today reported its financial results for the second fiscal quarter ended September 30, 2021 and...
Nov 08, 2021 04:45 pm ET
Roivant to Report Financial Results for the Quarter Ended September 30, 2021 on Monday, November 15, 2021
Roivant Sciences (Nasdaq: ROIV), a biopharmaceutical company dedicated to improving the delivery of healthcare to patients, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Monday, November 15, 2021 to report...
Oct 29, 2021 07:52 am ET
Roivant Discovery Announces 2021 Open Science Fellows
Roivant Discovery, the drug discovery engine for Roivant Sciences (Nasdaq
Oct 01, 2021 08:00 am ET
Roivant Sciences Announces Close of Business Combination with Montes Archimedes Acquisition Corp. and Concurrent PIPE Financing
Roivant Sciences, a biopharmaceutical company dedicated to improving the delivery of healthcare to patients, today announced that it has closed its business combination with Montes Archimedes Acquisition Corp. (Nasdaq: MAAC), a special purpose...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.